As HDAC inhibitors display anticancer efficacy in different cancers in vitro and in vivo (Beckers et al., 2007; Kim et al., 2013b), they can be applied in clinical practice for more tumors such as BC. The gene discussed is HDAC9; the disease is breast cancer.